Log in
Enquire now
‌

US Patent 10934279 GLP-1 receptor agonists and uses thereof

Patent 10934279 was granted and assigned to Pfizer Limited on March, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
109342790
Patent Inventor Names
Chris Limberakis0
Alan M. Mathiowetz0
Allyn T. Londregan0
Roger B. Ruggeri0
Scott W. Bagley0
Yajing Lian0
David A. Griffith0
David James Edmonds0
...
Date of Patent
March 2, 2021
0
Patent Application Number
164363110
Date Filed
June 10, 2019
0
Patent Citations
‌
US Patent 10676465 GLP-1 receptor agonists and uses thereof
‌
US Patent 10683281 GLP-1 receptor agonists and uses thereof
Patent Citations Received
‌
US Patent D1011080 Yoga storage rack
0
‌
US Patent 11858916 GLP-1 receptor agonists and uses thereof
0
Patent Primary Examiner
‌
Rita J Desai
0
Patent abstract

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10934279 GLP-1 receptor agonists and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.